AI
ELEV

Allostery Investments’s Elevation Oncology ELEV Stock Holding History

Allostery Investments’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-432,206
Closed -$243K – 46
2024
Q4 		$243K Buy
+432,206
New +$255K 0.25% 37

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Allostery Investments's ELEV Position: Q1 2025 in Review

Allostery Investments sold out of Elevation Oncology (ELEV) in Q1 2025, closing a stake of 432,206 shares — an estimated $243K sold.

Allostery Investments first reported a position in ELEV in Q4 2024 and held it in 1 quarter. The position peaked at $243K in Q4 2024. 72 funds tracked by Wall St. Rank hold ELEV as of Q1 2025.

  • Allostery Investments reported no remaining Elevation Oncology position as of Q1 2025 after selling out during the quarter.
  • Allostery Investments sold 432,206 Elevation Oncology shares in Q1 2025, an estimated $243K.
  • Allostery Investments first reported a position in Elevation Oncology in Q4 2024 and held it in 1 quarter.
  • Allostery Investments's Elevation Oncology position peaked at $243K in Q4 2024.
  • 72 funds tracked by Wall St. Rank held Elevation Oncology as of Q1 2025.

Based on Allostery Investments's 13F filing for Q1 2025, filed 15 May 2025.